Mylan NV reminds several batches of medicines for valsartan blood pressure in Romania
The United States, after it was discovered that it contains a cancer probability that causes impurity, is the latest recall amid more global security concerns.
The company's shares, which yesterday revealed a warning letter received from the US Food and Drug Administration (FDA) earlier this month, fell nearly two percent to $ 33.91 after the bell.
The news comes a day after the European Union authorities effectively banned the sale of valsartan manufactured by an Indian-based Mylan unit after some N-nitrozodiethylamine (NDEA) was found to contain the same impurity.
Mylan said yesterday he will remember at least 15 batches of valsartan-containing medicines distributed in the United States between March 2017 and November 2018 and manufactured by Mylan Pharmaceuticals and Mylan Laboratories.
In the past year, global health authorities cracked valsartan and drug-containing drugs as active ingredient after several batches were found to contain NDEA and a second carcinogen, N-nitrozodimethylamine (NDMA).
US FDA last month stopped importing drug ingredients or medicines containing ingredients produced in a factory owned by a Chinese valsartan manufacturer, Zhejiang Huahai Pharmaceuticals.
Huahai recalled the product affected by US consumers in July.